Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (GB:0HD2)
LSE:0HD2
Holding GB:0HD2?
Track your performance easily
See the Price Targets and Ratings of:
0HD2 Analyst Ratings
Strong Buy
16 Buy
5 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
0HD2 Stock 12 Month Forecast
Average Price Target
$297.53
▲(13.34% Upside)
| Highest Price Target$400.00 | Average Price Target$297.53 | Lowest Price Target$163.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Stifel Nicolaus
Reiterated
08/30/24
H.C. Wainwright
Reiterated
08/30/24
J.P. Morgan
Reiterated
08/26/24
BMO Capital
Reiterated
08/26/24
RBC Capital
Reiterated
08/26/24
Goldman Sachs
Upgraded
08/16/24
Barclays
Reiterated
08/02/24
TD Cowen
Assigned
08/02/24
Evercore ISI
Assigned
08/02/24
Chardan Capital
Reiterated
08/02/24
Morgan Stanley
$255→$275
Hold
4.75%
Upside
Reiterated
08/02/24
Alnylam Pharma (ALNY) Gets a Hold from Morgan Stanley
Oppenheimer
―
Hold
―
Reiterated
08/02/24
Alnylam Pharma (ALNY) Gets a Hold from Oppenheimer
Wells Fargo
$207→$233
Hold
-11.24%
Downside
Assigned
08/02/24
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT), Alnylam Pharma (NASDAQ: ALNY) and Omnicell (NASDAQ: OMCL)
Raymond James
$242→$275
Buy
4.75%
Upside
Reiterated
08/02/24
Alnylam price target raised to $275 from $242 at Raymond JamesAlnylam price target raised to $275 from $242 at Raymond James
Canaccord Genuity
$357→$366
Buy
39.42%
Upside
Reiterated
08/01/24
Alnylam Pharma Earns Buy Rating on Strong Earnings Performance and Positive Clinical Outlook
Best Analysts Covering Alnylam Pharma
Which Analyst Should I Follow If I Want to Buy GB:0HD2 and Sell After:
1 Month
xxx
Success Rate
16/27 ratings generated profit
Average Return
+1.27%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 59.26% of your transactions generating a profit, with an average return of +1.27% per trade.
3 Months
xxx
Success Rate
18/29 ratings generated profit
Average Return
+5.97%
assigned a xxx
rating 30 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 62.07% of your transactions generating a profit, with an average return of +5.97% per trade.
1 Year
Success Rate
16/20 ratings generated profit
Average Return
+37.49%
reiterated a buy rating 5 months ago
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +37.49% per trade.
2 Years
xxx
Success Rate
28/29 ratings generated profit
Average Return
+57.92%
assigned a xxx
rating 30 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 96.55% of your transactions generating a profit, with an average return of +57.92% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
0HD2 Analyst Recommendation Trends
Rating
Apr 24
May 24
Jun 24
Jul 24
Aug 24
Strong Buy
22
12
11
6
5
Buy
7
6
20
18
33
Hold
13
8
12
11
13
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
42
26
43
35
51
Each month's total comprises the sum of three months' worth of ratings.
0HD2 Financial Forecast
0HD2 Stock Forecast FAQ
What is GB:0HD2’s average 12-month price target, according to analysts?
Based on analyst ratings, Alnylam Pharmaceuticals’s 12-month average price target is $297.53.
What is GB:0HD2’s upside potential, based on the analysts’ average price target?
Alnylam Pharmaceuticals has 13.34% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Alnylam Pharmaceuticals a Buy, Sell or Hold?
Alnylam Pharmaceuticals has a consensus rating of Strong Buy, which is based on 16 buy ratings, 5 hold ratings and 0 sell ratings.
What is Alnylam Pharmaceuticals’s share price target?
The average share price target for Alnylam Pharmaceuticals is $297.53. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $400.00 ,and the lowest forecast is $163.00. The average share price target represents 13.34% Increase from the current price of $262.52.
The highest analyst share price target is $400.00 ,and the lowest forecast is $163.00. The average share price target represents 13.34% Increase from the current price of $262.52.
What do analysts say about Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.
How can I buy shares of Alnylam Pharmaceuticals?
To buy shares of GB:0HD2, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.